$KLRS News

Wedbush Initiates Coverage On Kalaris Therapeutics with Outperform Rating, Announces Price Target of $17

Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Therapeutics Q1 EPS $(0.46) Beats $(0.53) Estimate

Kalaris Therapeutics shares are trading higher after Morgan Stanley initiated its coverage on the stock with an Overweight rating and announced a price target of $14.

Kalaris Therapeutics shares are trading higher after Morgan Stanley initiated its coverage on the stock with an Overweight rating and announced a price target of $14.

Morgan Stanley Initiates Coverage On Kalaris Therapeutics with Overweight Rating, Announces Price Target of $14

Kalaris Therapeutics Launches Up To $100M At-The-Market Stock Offering Agreement With TD Cowen

Kalaris Therapeutics CFO Matthew Gall Resigns, Effective April 14

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Q4 EPS $(0.44) Beats $(0.56) Estimate

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Kalaris Therapeutics To Present Clinical Data From Phase 1 Study Of TH103 At 49th Annual Meeting Of Macula Society

Chardan Capital Initiates Coverage On Kalaris Therapeutics with Buy Rating, Announces Price Target of $19

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris Therapeutics Data From Phase 1a Single Dose Study Of TH103 Demonstrates Showed Mean 10-letter Gain In Visual Acuity, Rapid; TH103 Was Generally Well Tolerated